Keros Therapeutics, Inc. (KROS) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$10.68

From 52W high−49.36%

Volume210645.00

Market cap$219.29M

P/E (TTM)—

P/S (TTM)14.6x

Div yield—

Key dataOct 19, 2026

Open

$10.68

From 52W high

−49.36%

Volume

210645.00

Market cap

$219.29M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.3x

P/E (TTM)

—

RSI (14)

45.5

MomentumView details →

1D Return

+3.75%

YTD Return

−46.32%

SummaryUpdated Jun 1, 2026

Keros Therapeutics, Inc. (NASDAQ:KROS) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Lexington, Massachusetts. The company went public in April 2020 and focuses on developing novel treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. Keros operates in the specialized field of protein therapeutics and small molecule drugs, targeting conditions affecting blood cell production and bone health.

Ask drillr about Keros Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.3x

EV/Sales

−1.5x

P/S (TTM)

14.6x

P/B (TTM)

0.8x

ProfitabilityView details →

Gross Margin

94.68%

Net Margin

−553.88%

EBITDA Margin

−562.79%

ROE (TTM)

−31.70%

ROA (TTM)

−28.91%

Asset Turnover

0.05x

GrowthView details →

Revenue YoY

−93.55%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+3920.32%

EPS CAGR 3Y

+146.80%

EBITDA YoY

—

MomentumView details →

1D Return

+3.75%

YTD Return

−46.32%

1Y Return

−28.04%

RSI (14)

45.5

vs 50D SMA

−2.05%

vs 200D SMA

−11.82%

Capital & dividendView details →

Debt/Equity

0.06x

Current Ratio

21.96x

Quick Ratio

21.96x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.45

EPS Surprise

−8.21%

Beats (12Q)

6/12

Next Q EPS Est

−$1.93

Avg Surprise (4Q)

−7.86%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

15.01M

Net Income (TTM)

−83.16M

Op. CF (TTM)

−47.99M

Next earningsNov 4, 2026 →

Latest newsMore news →

Keros Therapeutics dosed the first patient in a Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy.22d ago

Keros Therapeutics' board approved a $5 million share repurchase program of its common stock, following receipt of a $20 million development milestone payment from Takeda Pharmaceuticals under the elritercept license agreement.42d ago

Similar companies

Larimar Therapeutics, Inc.LRMR Zentalis Pharmaceuticals, Inc.ZNTL Alector, Inc.ALEC Fate Therapeutics, Inc.FATE Lyell Immunopharma, Inc.LYEL Greenwich LifeSciences, Inc.GLSI Find similar companies →

Latest newsMore news →

Keros Therapeutics dosed the first patient in a Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy.22d ago Keros Therapeutics' board approved a $5 million share repurchase program of its common stock, following receipt of a $20 million development milestone payment from Takeda Pharmaceuticals under the elritercept license agreement.42d ago Keros Therapeutics will receive a $20 million development milestone payment from Takeda after the first patient was dosed in the ELRiSE MDS clinical trial.82d ago